NuVasive (NSDQ:NUVA) said today it named Medtronic (NYSE:MDT) surgical innovations prez J. Barry as its new CEO, replacing Gregory Lucier, effective November 5. Barry will also join the company’s board of directors, where Lucier will continue to serve as board chair and aid in transition efforts, the San Diego-based company said. NuVasive also said that it promoted current strategy, […]
Clearside Biomedical posts Street-beating Q4, full year results
Shares in Clearside Biomedical (NSDQ:CLSD) fell today even though the biopharmaceutical company topped sales and earnings estimates on Wall Street with its fourth quarter and full year results. The Alpharetta, Ga.-based company posted a net loss of -$16.5 million on sales of $55,000 for the three months ended Dec. 31, for bottom-line loss of -70% on […]
Clearside Biomedical prices $85m underwritten offering
Clearside Biomedical (NSDQ:CLSD) priced 6,538,462 shares of its common stock at $13.00 apiece in an $85 million underwritten public offering that’s expected to close early next week. The Alpharetta, Ga.-based company is slated to use the funds to prepare and submit an application to the FDA for its suprachoroidal eye drug as a treatment for patients […]
Clearside Biomedical floats $75m public offering
Clearside Biomedical (NSDQ:CLSD) plans to offer $75 million in shares of its common stock in an underwritten public offering. The Alpharetta, Ga.-based company is slated to use the funds to prepare and submit an application to the FDA for its suprachoroidal eye drug as a treatment for patients with macular edema associated with non-infectious uveitis. Get […]
Clearside Biomedical enrolls first patient in Ph3 macular edema trial
Clearside Biomedical (NSDQ:CLSD) has enrolled the first patient in a Phase III trial evaluating its eye drug combined with an intravitreally-administered anti-VEGF agent as a treatment for macular edema associated with retinal vein occlusion. The company’s drug, CLS-TA, is a proprietary suspension of triamcinolone acetonide designed to be administered in the space located between the choroid […]
Clearside Biomedical shares soar after eye drug succeeds in Ph3 trial
Clearside Biomedical (NSDQ:CLSD) shares soared more than 50% in pre-market activity today after the company reported that its suprachoroidal eye drug succeeded in a pivotal Phase III trial of patients with macular edema associated with non-infectious uveitis. The company’s drug, CLS-TA, is a proprietary suspension of a corticosteroid, triamcinolone acetonide, designed to be administered to the […]
Clearside Biomedical misses Q3 earnings estimates
Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the company missed expectations on Wall Street with its third quarter results. The Alpharetta, Ga.-based company posted a net loss of -$18.3 million for the 3 months ended Sept. 30, for bottom-line loss of -226% compared with the same period last year. Get the full story at our […]
Clearside Biomedical misses EPS estimate in Q2
Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the biopharmaceutical company missed earnings expectations on Wall Street with its second quarter results. The Alpharetta, Ga.-based company posted a net loss of -$13.8 million on sales of $130,000 for the 3 months ended June 30, for bottom-line loss of -169% compared with the same period last year. Get […]
Clearside Biomedical launches Phase II diabetic macular edema trial
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema. The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent. Get the full story at our […]
Clearside Biomedical highlights interim data from retreatment trial
Clearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration. Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion. Get the full story […]
Clearside Biomedical beats Q1 earnings consensus
Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 1st quarter results. The Alpharetta, Ga.-based company posted a net loss of -$10.4 million, or -41¢ per share, on sales of $5,000 for the 3 months ended March 31, for bottom-line loss of -47.5 % compared with […]
MassDevice Network
@MassDevice
LinkedIn